Reformulated Imatinib Eliminates Morphine Tolerance In Lab Studies
2/22/2012
By reformulating the common cancer drug imatinib (Gleevec®), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center. Narcotics such as morphine are a mainstay of chronic pain treatment...
Possible New Target For Cancer Therapy - Energy Network Within Cells
2/22/2012
Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB...
Early Cancer Detection Via New Blood Test: Research In The Early Stages Of Clinical Trials
2/22/2012
A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer. Prof. Kapelushnik of BGU's Faculty of Health Sciences and his team developed a device that illuminates cancer cells with less than a teaspoon of blood...
Drug Combo Kills Pancreatic Cancer Cells
2/21/2012
Combining gemcitabine with MRK003, an experimental drug, triggers a chain of events leading to pancreatic cancer cell death, researchers from Cambridge reported in the Journal of Experimental Medicine. The researchers explained that when the two drugs are combined, the effect of each one is multiplied, thus intensifying the destruction of pancreatic cancer cells...
Zelboraf (vemurafenib), For Deadly Skin Cancer, Approved In Europe
2/21/2012
Zelboraf (vemurafenib), manufactured by Roche, has been approved by the European Commission, for treating patients with BRAF V600 mutation-positive metastatic melanoma, a deadly, and dangerous type of skin cancer. Zelboraf works by seeking out the mutated parts of the BRAF protein, found in about 50% of all melanoma cases, and blocking its action. Hal Barron, M.D...
Zelboraf (vemurafenib), For Deadly Skin Cancer, Approved In Europe
2/21/2012
Zelboraf (vemurafenib), manufactured by Roche, has been approved by the European Commission, for treating patients with BRAF V600 mutation-positive metastatic melanoma, a deadly, and dangerous type of skin cancer. Zelboraf works by seeking out the mutated parts of the BRAF protein, found in about 50% of all melanoma cases, and blocking its action. Hal Barron, M.D...
A Promising Novel Therapeutic Target In Cancer - The USP15 Biological Thermostat
2/21/2012
After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr...
A Model For Collaboration - Indiana Clinical And Translational Science Institute HUB
2/21/2012
At a time when medical research increasingly requires collaboration by large numbers of busy people, the Indiana Clinical and Translational Science Institute HUB offers a model for using advanced information technology to link scientists, health providers, community partners and others for the purpose of accelerating clinical and translational research...
Cancer Evolution Discussed At Prestigious Conference
2/21/2012
Professor Mike Stratton, Director of the Wellcome Trust Sanger Institute, talked about 'the evolution of the cancer genome' at the prestigious 2012 American Association for the Advancement of Science annual meeting. The AAAS annual meeting is one of the world's most widely recognized science events...
Some 90 percent of people are exposed to the Epstein Barr virus (EBV) at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells...